U.S. Markets close in 2 hrs 56 mins

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
59.21+0.71 (+1.21%)
As of 01:03PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close58.50
Bid58.88 x 800
Ask59.08 x 1200
Day's Range57.45 - 59.87
52 Week Range28.40 - 66.00
Avg. Volume962,798
Market Cap4.823B
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Motley Fool

    Why Intra-Cellular Therapies Stock Rose 21.4% This Week

    Intra-Cellular Therapies (NASDAQ: ITCI), a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global Market Intelligence. The drug was initially approved by the Food and Drug Administration (FDA) in the first quarter of 2020 as a treatment for adult schizophrenia. In late December, an additional indication, as a monotherapy or adjunct treatment for bipolar depression, was approved by the FDA.

  • Investor's Business Daily

    Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating

    Intra-Cellular Therapies shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

  • Motley Fool

    Why Intra-Cellular Therapies Trounced the S&P 500 Today

    For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year. Caplyta is a relatively new drug on the market, having won Food and Drug Administration (FDA) approval last December. Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit.